272 related articles for article (PubMed ID: 11263938)
1. Risk of endometrial carcinoma associated with BRCA mutation.
Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
[TBL] [Abstract][Full Text] [Related]
2. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
3. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
4. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
5. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
6. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
7. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
Levine DA; Argenta PA; Yee CJ; Marshall DS; Olvera N; Bogomolniy F; Rahaman JA; Robson ME; Offit K; Barakat RR; Soslow RA; Boyd J
J Clin Oncol; 2003 Nov; 21(22):4222-7. PubMed ID: 14615451
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
Gershoni-Baruch R; Dagan E; Fried G; Kepten I; Robinson E
Eur J Hum Genet; 1999; 7(7):833-6. PubMed ID: 10573018
[TBL] [Abstract][Full Text] [Related]
10. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
11. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
12. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
13. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
14. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.
Drucker L; Stackievitz R; Shpitz B; Yarkoni S
Anticancer Res; 2000; 20(1B):559-61. PubMed ID: 10769725
[TBL] [Abstract][Full Text] [Related]
15. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
16. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
17. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.
Chen-Shtoyerman R; Figer A; Fidder HH; Rath P; Yeremin L; Bar Meir S; Friedman E; Theodor L
Br J Cancer; 2001 Feb; 84(4):475-7. PubMed ID: 11207040
[TBL] [Abstract][Full Text] [Related]
18. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
Levine DA; Boyd J
Cancer Res; 2001 Feb; 61(3):908-11. PubMed ID: 11221880
[TBL] [Abstract][Full Text] [Related]
19. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
20. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]